Octreotide implant having a release agent
First Claim
Patent Images
1. A formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μ
- g to about 800 μ
g per day over about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent with a molecular weight of at least about 1000 Daltons.
12 Assignments
0 Petitions
Accused Products
Abstract
Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.
-
Citations
23 Claims
-
1. A formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μ
- g to about 800 μ
g per day over about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent with a molecular weight of at least about 1000 Daltons. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
- g to about 800 μ
-
17. A method of decreasing GH levels or IGF-1 levels in a subject and/or treating an octreotide-sensitive disease, disorder or symptom, the method comprising subcutaneously implanting at least one dry implantable device comprising a preparation encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μ
- g to about 800 μ
g per day about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent having a molecular weight of at least 1000 Daltons. - View Dependent Claims (18, 19, 20, 21, 22)
- g to about 800 μ
-
23. A kit comprising a formulation for the controlled release of octreotide after implantation into a subject comprising a preparation substantially encased in a polyurethane based hydrophilic polymer, wherein the preparation comprises octreotide, wherein the formulation is effective to permit release of octreotide at a rate of about 30 μ
- g to about 800 μ
g per day over about six months in vivo, and wherein the polyurethane based hydrophilic polymer but not the preparation further comprises a release agent with a molecular weight of at least about 1000 Daltons.
- g to about 800 μ
Specification